CBDP belongs to the homologue series of cannabinoids first characterised in a 2019 paper by Citti and colleagues, the same study that identified THCP. It is present in trace quantities in Cannabis sativa L. and is understood to arise via the same biosynthetic pathway as CBD , through enzymatic decarboxylation of its acidic precursor, CBDPA (cannabidiphorolic acid). Because its natural abundance is extremely low, most research-grade material is produced through partial synthesis from plant-derived CBD.
The extended heptyl side chain is the defining structural feature. In related phytocannabinoids, longer alkyl chains generally correlate with altered binding geometry at cannabinoid receptors, though the binding affinity data for CBDP specifically are limited. Unlike CBD, which shows low direct affinity for CB1 and CB2 receptors, CBDP's receptor interaction profile has not yet been characterised in detail in the published literature. Its relationship to the endocannabinoid system (ECS) beyond the canonical CB1/CB2 axis , including any interaction with TRP channels, GPR55, or other ECS-adjacent targets , remains an open question.
As of the time of writing, peer-reviewed pharmacological studies on CBDP are sparse. The compound has not been assessed for safety or efficacy by the Therapeutic Goods Administration (TGA), holds no approved therapeutic indication in Australia, and is not listed as a separately scheduled substance in the current Poisons Standard; though it would fall within the scheduling entry for cannabis and cannabinoids where applicable. Researchers have noted CBDP as a point of interest precisely because CBD's own pharmacology is well mapped, making the homologue a potential comparator in future receptor studies.
CBDP should not be confused with THCP (tetrahydrocannabiphorol), its psychoactive structural counterpart in the same homologue series. Both were reported in the same 2019 identification study, but their chemistries, receptor affinities, and regulatory contexts differ.
Sources:
- Citti C et al., "A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol", Nature/Scientific Reports via NCBI
- Scheduling Delegate's Final Decisions, March 2020, Therapeutic Goods Administration (TGA)
- Cannabinoid Pharmacology and Receptor Classification; StatPearls via NCBI